Targeting WSTF Protein as a Strategy to Manage Chronic Inflammation Without Impairing Acute Immune Response

Chronic inflammation is characterized by the immune system remaining persistently active, leading to long-term tissue damage and contributing to diseases such as arthritis, cancer, and autoimmune disorders. This ongoing inflammatory response differs from acute inflammation, which is a quick, protective reaction to infections or injuries. Recently, researchers from Mass General Brigham have identified a promising approach to selectively suppress chronic inflammation without compromising the body's ability to respond to immediate threats.

The key discovery centers around a protein called WSTF. The team found that WSTF plays a crucial role in the regulation of chronic inflammation. In inflamed human cells, WSTF interacts within the cell nucleus, where its degradation exposes pro-inflammatory genes, thereby intensifying inflammation. Importantly, loss of WSTF was observed only in instances of chronic inflammation, and not in acute responses, suggesting a distinct mechanism that can be targeted selectively.

Further studies in mouse models of aging and cancer demonstrated that reducing WSTF leads to increased inflammation, confirming its role in maintaining inflammatory balance. Building on these insights, the researchers developed a therapeutic strategy aimed at restoring WSTF levels, which successfully suppressed chronic inflammation in models of age-related diseases, metabolic dysfunction, and osteoarthritis. Tissue analysis from patients with liver disease (MASH) and osteoarthritis revealed a loss of WSTF in affected tissues, strengthening the potential clinical relevance.

The therapeutic approach involving WSTF restoration shows promise, as initial results indicate it can effectively reduce chronic inflammation. This breakthrough opens new pathways for treating chronic inflammatory conditions while preserving the immune system's capacity to handle acute challenges, such as infections. Moving forward, further research aims to validate WSTF-targeted therapies across broader disease settings and explore other related proteins involved in inflammation control.

The findings, published in Nature, mark a significant step toward more precise and effective treatments for chronic inflammatory diseases, potentially improving outcomes for millions affected worldwide.